Ropotrectinib

Independent reference data for Ropotrectinib (CAS 1802220-02-5), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Repotrectinib is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). It is also indicated in patients ≥12 years of age and older with neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors which are locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have experienced disease progression following treatment or have no satisfactory alternative.Repotrectinib is a small molecule inhibitor of the proto-oncogene tyrosine-protein kinase ROS1 and of tropomyosin receptor tyrosine kinases (TRK-A, -B and -C) and is used to treat adults with non-small cell lung cancer. Repotrectinib is associated with a moderate rate of mild transient elevations in serum aminotransferase levels during therapy but has not been linked to episodes of clinically apparent liver injury with jaundice.

Synonyms and trade names

Repotrectinib; 1802220-02-5; TPX-0005; Augtyro; 08O3FQ4UNP; repotrectinibum; (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE; (3R,6S,)-45-Fluoro-3,6-dimethyl-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenanonaphan-9-one; RefChem:178876; Multikinase Inhibitor TPX-0005; Multi-kinase Inhibitor TPX-0005; ALK/ROS1/NTRK/SRC/FAK Multikinase Inhibitor TPX-0005; Ropotrectinib; Repotrectinib [USAN]; TPX0005; Repotrectinib(TPX-005)

What the public record says

Ropotrectinib · CAS 1802220-02-5 · C18H18FN5O2. UNII 08O3FQ4UNP.

Source: PubChem / Wikidata; the batch COA governs where values differ.